Clinical Report: Amyloid Seeds Emerge as Blood Biomarker

Overview

A blood test measuring amyloid beta aggregation seeding activity distinguished Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease from normal cognition and other dementias. The study involved 549 patients and demonstrated high diagnostic performance with area under the curve values of 0.93 and 0.91 for Alzheimer’s disease versus normal cognition and non-Alzheimer’s dementia, respectively.

Background

The identification of reliable biomarkers for Alzheimer’s disease is critical for early diagnosis. Traditional diagnostic methods often rely on clinical criteria, which may not provide the necessary specificity. The emergence of blood-based biomarkers, such as amyloid beta seeding activity, offers a potential avenue for improving diagnostic accuracy.

Data Highlights

Key Findings

• The blood test distinguished Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease from normal cognition and other dementias.
• Amyloid beta seeding activity was significantly higher in patients with Alzheimer’s disease compared to cognitively unimpaired individuals.
• The assay demonstrated an area under the curve of 0.93 for distinguishing Alzheimer’s disease from normal cognition.
• In a subgroup analysis, the plasma assay outperformed cerebrospinal fluid biomarkers in distinguishing Alzheimer’s disease from non-Alzheimer’s dementia.
• Higher plasma seeding activity correlated with poorer cognitive performance and greater dementia severity.

Clinical Implications

The findings indicate that measuring amyloid beta seeding activity in blood could serve as a diagnostic tool for Alzheimer’s disease and related conditions.

Conclusion

The study highlights the potential of blood-based biomarkers, specifically amyloid beta seeding activity, in improving the diagnostic landscape for Alzheimer’s disease.

Related Resources & Content

1. Chinese Medical Journal, 2024 -- Amyloid Seeds Emerge as Blood Biomarker
2. the pathologist, 2026 -- Tau Biomarker Expands Beyond Alzheimer’s
3. Annals of Neurology, 2024 -- Cerebrospinal Fluid Amyloid-β Biomarkers Predict Future Hemorrhage in Patients with Cerebral Amyloid Angiopathy
4. the pathologist, 2024 -- Apex of Understanding
5. The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD)
6. the pathologist — RNA Test Advances Alzheimer's Detection
7. The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care - PMC
8. From Cerebrospinal Fluid to Blood Draw: Plasma p-Tau217 as a Non-Invasive Biomarker for Alzheimer’s Disease: A Fagan Nomogram-Based Meta-Analytic Study - PMC
9. Detection of plasma Aβ seeding activity by a newly developed analyzer for diagnosis of Alzheimer’s disease - PMC